NetraMark Holdings Inc. announced the release of its Alzheimer's Disease (AD) white paper further demonstrating the capabilities of NetraAl to uncover new insights within patient populations of heterogeneous disorders with unmet needs. The NetraAl technology discovered these segments while it learned how to separate controls versus AD from samples derived from postmortem brain samples. NetraAI's outputs are clear and interpretable for human interrogation, which is critical for decision making in a clinical trial.

Furthermore, the additional results discussed in the white paper corroborate findings established in the field, including characteristics contributing to disease etiology and sex-based differences in incidence. A unique aspect of NetraAI's findings was the specific implication of GTSE1 and TUBB1 as being important factors for these subtypes of AD, in addition to other genes that are being considered as potential therapeutic targets for neurodegeneration with one of partners. This can have consequences for future clinical trials by those studying AD.

Significance of findings AD is widely known as a heterogeneous disease, yet often AD drug trials have broad inclusion criteria and don't account for disease heterogeneity in trial design. This of itself is an important technological facet of the NetraAl technology. Further, the specific insights derived from this project for AD patients can help drive clinical trials for this disease forward by improving how AD patients can be matched with drugs, depending on their different mechanisms of action.

Furthermore, Dr. Donald Weaver, MD, PhD, FRCPC, FCAHS and current Research Director and Institute Co-Director at therembil Brain Institute at the University Health Network (UHN), and the Canada Research Chair, Tier 1, Division of Neurology, Department of Medicine, Faculty of Medicine, University of Toronto, who has won multiple national awards in chemistry and neurology and has devised two compounds that have reached phase III trials, has reviewed output from the NetraAl technology in relation to a NetraMark AD partner project, had this to say about NetraAl and its capabilities: Alzheimer's research has been dominated for decades by the protein misfolding theory known as the 'amyloid hypothesis'. The failure of this hypothesis to deliver a cure highlights the crucial need to apply cutting edge technologies like NetraAl and to generate new ideas in order to improve clinical trials in the pursuit of truly effective treatments for AD.